de Almeida Hiram Larangeira, Sartori Debora Sarzi, de Almeida Antônia Larangeira, Ruas Caroline Pires, Zerwes Gustavo
Department of Dermatology, Catholic and Federal University of Pelotas, Rio Grande, Brazil.
Post-Graduation Program in Health Sciences, Catholic University of Pelotas, Rio Grande, Brazil.
Int J Trichology. 2020 May-Jun;12(3):129-131. doi: 10.4103/ijt.ijt_69_20. Epub 2020 Aug 14.
Oral inhibitors of epidermal growth factor receptor may have a wide range of cutaneous manifestations. Hair manifestations are observed in 10%-20% of the patients. At the ultrastructural level erlotinib-induced hair changes were already described as acquired pili torti et canaliculi. We examined a 78-year-old female patient, with lung carcinoma, taking gefitinib for 15 months. The treatment has no side effects with good tolerance and tumor response. Although the patient had not observed any change on the hairs under the therapy, some specimens were obtained to be examined in natura with scanning electron microscopy. Under low magnification incipient grooving was observed on the hair surface, tortions or angulations of the hair shaft were not found. With higher magnifications the surface grooving was even more evident. Our findings show that gefitinib may cause subclinical hair changes, similar to those described at the ultrastructural level with erlotinib.
表皮生长因子受体口服抑制剂可能有广泛的皮肤表现。10%-20%的患者会出现毛发表现。在超微结构水平上，厄洛替尼引起的毛发变化已被描述为获得性扭曲发及发内小管。我们检查了一名78岁的女性肺癌患者，她服用吉非替尼15个月。治疗耐受性良好且肿瘤反应良好，无副作用。尽管患者在治疗期间未观察到毛发有任何变化，但仍采集了一些标本用扫描电子显微镜进行原位检查。在低倍镜下观察到毛发表面开始出现沟纹，未发现毛干扭曲或成角。在高倍镜下，表面沟纹更加明显。我们的研究结果表明，吉非替尼可能会引起亚临床毛发变化，类似于在超微结构水平上用厄洛替尼所描述的变化。
